Research & Literature

[Diagnostic value of combined detection of HNF-1β and Napsin A in the diagnosis of ovarian clear cell carcinoma].

Wang J, Li Q, Cheng X, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology 2015; (44(12)):874-8.

Mucinous ovarian cancer: A therapeutic review.

Xu W, Rush J, Rickett K, Coward JI

Critical reviews in oncology/hematology 2016; (102()):26-36.

Salvage Therapy for Patients With Germ Cell Tumor.

Rashdan S, Einhorn LH

Journal of oncology practice 2016; (12(5)):437-43 doi:10.1200/JOP.2016.011411.

Genetic and molecular changes in ovarian cancer.

Hollis RL, Gourley C

Cancer biology & medicine 2016; (13(2)):236-47 doi:10.20892/j.issn.2095-3941.2016.0024.

Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.

Pokharel HP, Hacker NF, Andrews L

The Australian & New Zealand journal of obstetrics & gynaecology 2016; (56(6)):633-638 doi:10.1111/ajo.12504.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B

Expert review of anticancer therapy 2017; (17(2)):109-117 doi:10.1080/14737140.2017.1272414.

Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.

Gockley A, Melamed A, Bregar AJ, et al.

Obstetrics and gynecology 2017; (129(3)):439-447 doi:10.1097/AOG.0000000000001867.

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Gershenson DM, Bodurka DC, Coleman RL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(10)):1103-1111 doi:10.1200/JCO.2016.71.0632.

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.

Färkkilä A, Haltia UM, Tapper J, et al.

Annals of medicine 2017; (49(5)):435-447 doi:10.1080/07853890.2017.1294760.

Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Park HK, Ruterbusch JJ, Cote ML

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2017; (26(10)):1511-1518 doi:10.1158/1055-9965.EPI-17-0290.

Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.

Yang C, Sun L, Zhang L, et al.

The American journal of surgical pathology 2018; (42(2)):160-171 doi:10.1097/PAS.0000000000000951.

SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.

Berg KB, Schaeffer DF

Archives of pathology & laboratory medicine 2017; (141(10)):1428-1433 doi:10.5858/arpa.2016-0243-RS.

Detection of Aristaless-related homeobox protein in ovarian sex cord-stromal tumors.

Knific T, Frković Grazio S, Rižner TL

Experimental and molecular pathology 2018; (104(1)):38-44 doi:10.1016/j.yexmp.2017.12.005.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, et al.

Gynecologic oncology 2019; (153(2)):304-311 doi:10.1016/j.ygyno.2019.02.005.

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

Champer M, Miller D, Kuo DY

Gynecologic oncology reports 2019; (28()):26-28 doi:10.1016/j.gore.2019.01.007.

Mucinous Ovarian Carcinoma.

Morice P, Gouy S, Leary A

The New England journal of medicine 2019; (380(13)):1256-1266 doi:10.1056/NEJMra1813254.

Mucinous Ovarian Tumors.

Mills AM, Shanes ED

Surgical pathology clinics 2019; (12(2)):565-585 doi:10.1016/j.path.2019.01.008.

Practical Review of Ovarian Sex Cord-Stromal Tumors.

Hanley KZ, Mosunjac MB

Surgical pathology clinics 2019; (12(2)):587-620 doi:10.1016/j.path.2019.02.005.

Germ Cell Tumors of the Female Genital Tract.

Euscher ED

Surgical pathology clinics 2019; (12(2)):621-649 doi:10.1016/j.path.2019.01.005.

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Meagher NS, Wang L, Rambau PF, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(12)):1834-1846 doi:10.1038/s41379-019-0302-0.

Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.

Marko J, Marko KI, Pachigolla SL, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(4)):982-997 doi:10.1148/rg.2019180221.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, et al.

Nature communications 2019; (10(1)):3935 doi:10.1038/s41467-019-11862-x.

Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics.

Rabban JT, Karnezis AN, Devine WP

Histopathology 2020; (76(1)):11-24 doi:10.1111/his.13978.

Low-grade serous ovarian carcinoma: A comprehensive literature review.

Goulding EA, Simcock B, McLachlan J, et al.

The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(1)):27-33 doi:10.1111/ajo.13105.

Low-grade serous ovarian cancer: State of the science.

Slomovitz B, Gourley C, Carey MS, et al.

Gynecologic oncology 2020; (156(3)):715-725 doi:10.1016/j.ygyno.2019.12.033.

Low-grade Serous Tumors: Are We Making Progress?

Pauly N, Ehmann S, Ricciardi E, et al.

Current oncology reports 2020; (22(1)):8 doi:10.1007/s11912-020-0872-5.

Rare ovarian tumors: an update on diagnosis and treatment.

Debuquoy C, Romeo C, Vanacker H, Ray-Coquard I

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):879-887 doi:10.1136/ijgc-2020-001235.

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Martins FC, Couturier DL, Paterson A, et al.

British journal of cancer 2020; (123(5)):793-802 doi:10.1038/s41416-020-0900-0.

HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors.

Gallo A, Fankhauser C, Hermanns T, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(11)):2354-2360 doi:10.1038/s41379-020-0597-x.

ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.

Sessa C, Schneider DT, Planchamp F, et al.

The Lancet. Oncology 2020; (21(7)):e360-e368 doi:10.1016/S1470-2045(20)30091-7.

The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.

Cobb LP, Sun CC, Iyer R, et al.

Gynecologic oncology 2020; (158(3)):653-658 doi:10.1016/j.ygyno.2020.06.498.

Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.

Nica A, Lee JYJ, Hong NL, May T

Gynecologic oncology 2021; (160(1)):206-213 doi:10.1016/j.ygyno.2020.09.051.

Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.

Voutsadakis IA

Cancer management and research 2020; (12()):10423-10437 doi:10.2147/CMAR.S249540.

Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors.

Moro F, Castellano LM, Franchi D, et al.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (57(6)):987-994 doi:10.1002/uog.23529.

Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.

Vasta FM, Dellino M, Bergamini A, et al.

Biomedicines 2020; (8(12)) doi:10.3390/biomedicines8120554.

Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management.

Al Harbi R, McNeish IA, El-Bahrawy M

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; (31(2)):161-168 doi:10.1136/ijgc-2020-002018.

Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

Dundr P, Singh N, Nožičková B, et al.

Diagnostic pathology 2021; (16(1)):20 doi:10.1186/s13000-021-01079-2.

Mixed ovarian germ cell tumor in a child: A case report of a rare association.

Benradi L, El Haissoufi K, Ammor A, et al.

Annals of medicine and surgery (2012) 2021; (65()):102237 doi:10.1016/j.amsu.2021.102237.

What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors.

De Leo A, Santini D, Ceccarelli C, et al.

Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040697.

The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.

Hemmingsen CH, Kjaer SK, Bennetsen AKK, et al.

Gynecologic oncology 2021; (162(2)):469-474 doi:10.1016/j.ygyno.2021.05.008.

Comparison of surgical and oncologic outcomes in patients with clear cell ovarian carcinoma associated with and without endometriosis.

Charatsingha R, Hanamornroongruang S, Benjapibal M, et al.

Archives of gynecology and obstetrics 2021; (304(6)):1569-1576 doi:10.1007/s00404-021-06096-6.

A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Falzone L, Scandurra G, Lombardo V, et al.

International journal of oncology 2021; (59(1)).

Recurrent gynandroblastoma of the ovary with germline DICER1 mutation: A case report and review of the literature.

Mercier AM, Zorn KK, Quick CM, Huffman LB

Gynecologic oncology reports 2021; (37()):100806 doi:10.1016/j.gore.2021.100806.

Sertoli-Leydig cell tumor of ovary in children: A report of two cases, including retiform variant.

Sarkar P, Sengupta M, Chatterjee U, Ghosh D

Indian journal of pathology & microbiology 2021; (64(3)):559-562 doi:10.4103/IJPM.IJPM_443_20.

Prognostic significance of tumor laterality in advanced ovarian cancer.

Yamada Y, Mabuchi S, Kawahara N, Kawaguchi R

Obstetrics & gynecology science 2021; (64(6)):524-531 doi:10.5468/ogs.21176.

Fertility-Sparing Surgery for Ovarian Cancer.

Canlorbe G, Chabbert-Buffet N, Uzan C

Journal of clinical medicine 2021; (10(18)) doi:10.3390/jcm10184235.

New therapeutic opportunities for women with low-grade serous ovarian cancer.

Moujaber T, Balleine RL, Gao B, et al.

Endocrine-related cancer 2021; (29(1)):R1-R16.

Multidisciplinary management of ovarian germ cell tumours-a single institutional study from India.

Ganguly S, Gargy S, Basu A, et al.

Ecancermedicalscience 2021; (15()):1290 doi:10.3332/ecancer.2021.1290.

Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.

Wang B, Chao S, Guo B

Journal of clinical laboratory analysis 2022; (36(2)):e24165 doi:10.1002/jcla.24165.

A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.

Chelariu-Raicu A, Holley E, Mayr D, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(5)):662-668 doi:10.1136/ijgc-2021-003104.

Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report.

Silva R, Moran B, Das S, et al.

Case reports in women's health 2022; (34()):e00395 doi:10.1016/j.crwh.2022.e00395.

Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Babaier A, Mal H, Alselwi W, Ghatage P

Diagnostics (Basel, Switzerland) 2022; (12(2)) doi:10.3390/diagnostics12020458.

A rare case of ovarian gonadoblastoma flourishing into malignant mixed germ cell tumour with review of literature.

Patel T, Jakhetiya B, Jakhetiya A, Meena V

International cancer conference journal 2022; (11(2)):114-118 doi:10.1007/s13691-021-00531-w.

Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study.

Chou CY, Cheng WF, Chen MY, et al.

Cancers 2022; (14(7)) doi:10.3390/cancers14071746.

15-Year-Old Patient with an Unusual Alpha-Fetoprotein-Producing Sertoli-Leydig Cell Tumor of Ovary.

Serife K, Karampelas S, Hottat N, et al.

Case reports in obstetrics and gynecology 2022; (2022()):4759826 doi:10.1155/2022/4759826.

Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.

Sia TY, Manning-Geist B, Gordhandas S, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(8)):1017-1024 doi:10.1136/ijgc-2022-003430.

Differences in Characteristics and Outcomes Between Large-Cell Neuroendocrine Carcinoma of the Ovary and High-Grade Serous Ovarian Cancer: A Retrospective Observational Cohort Study.

Pang L, Guo Z

Frontiers in oncology 2022; (12()):891699 doi:10.3389/fonc.2022.891699.

The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.

Gershenson DM, Sun CC, Westin SN, et al.

Gynecologic oncology 2022; (165(3)):560-567 doi:10.1016/j.ygyno.2021.11.019.

Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.

Yamamoto E, Warigaya K, Kinoshita Y, et al.

Cancer reports (Hoboken, N.J.) 2022; (5(10)):e1676 doi:10.1002/cnr2.1676.

Incidence of lymph node metastasis in early-stage low-grade serous ovarian cancer: a systematic review.

Viveros-Carreño D, Rodriguez J, Pareja R

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(10)):1283-1288 doi:10.1136/ijgc-2022-003618.

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Armstrong DK, Alvarez RD, Backes FJ, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):972-980.

Could fertility-sparing surgery be considered for stage I ovarian sex cord-stromal tumors? A comparison of the Fine-Gray model with Cox model.

Sun D, Zhi ZF, Fan JT

Frontiers in oncology 2022; (12()):964181 doi:10.3389/fonc.2022.964181.

Primary mucinous ovarian cancer: options for surgery and chemotherapy.

Kurnit KC, Frumovitz M

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(11)):1455-1462 doi:10.1136/ijgc-2022-003806.

Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors.

Weidemann S, Noori NA, Lennartz M, et al.

Biomedicines 2022; (10(10)) doi:10.3390/biomedicines10102507.

Update on new treatments for rare ovarian tumours.

Quesada S, Bini M, Lebreton C, Ray-Coquard I

Current opinion in obstetrics & gynecology 2023; (35(1)):27-33 doi:10.1097/GCO.0000000000000836.

Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.

Dong S, Yu F, Liu Y, et al.

Ginekologia polska 2023; (94(10)):792-798 doi:10.5603/GP.a2022.0123.

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.

Zwimpfer TA, Tal O, Geissler F, et al.

Cancer treatment reviews 2023; (112()):102497 doi:10.1016/j.ctrv.2022.102497.

Disparity in the era of personalized medicine for epithelial ovarian cancer.

Devlin MJ, Miller RE

Therapeutic advances in medical oncology 2023; (15()):17588359221148024 doi:10.1177/17588359221148024.

Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?

Shamash J, Ng K

Expert review of anticancer therapy 2023; (23(2)):127-134 doi:10.1080/14737140.2023.2162042.

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.

Plett H, Ricciardi E, Vacaru V, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(5)):734-740 doi:10.1136/ijgc-2022-003854.

Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.

Foster KI, Shaw KRM, Jin J, et al.

Cancer 2023; (129(11)):1672-1680 doi:10.1002/cncr.34724.

[Treatments for rare ovarian tumors: What's new?]

Lebreton C, Quesada S, Bini M, et al.

Bulletin du cancer 2023; (110(7-8)):818-824 doi:10.1016/j.bulcan.2023.03.007.

The highs and lows of serous ovarian cancer.

Grisham RN, Manning-Geist BL, Chui MH

Cancer 2023; (129(17)):2613-2620 doi:10.1002/cncr.34903.

HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.

Smithgall MC, Yemelyanova A, Mathew S, et al.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2024; (43(2)):134-139 doi:10.1097/PGP.0000000000000966.

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel.

Neil AJ, Muto MG, Kolin DL, Konstantinopoulos PA

Gynecologic oncology reports 2023; (48()):101237 doi:10.1016/j.gore.2023.101237.

Current limits of conservative treatment in ovarian cancer.

Gracia M, Alonso-Espías M, Zapardiel I

Current opinion in oncology 2023; (35(5)):389-393 doi:10.1097/CCO.0000000000000970.

Obstetric Results after Fertility-Sparing Management of Non-Epithelial Ovarian Cancer.

Piątek S, Szymusik I, Sobiczewski P, et al.

Cancers 2023; (15(16)) doi:10.3390/cancers15164170.

Recurrent Granulosa Cell Tumor in a Postmenopausal Woman: A Case Report and Literature Review.

Dolkar T, Rayapureddy AK, Kadakia N, et al.

Cureus 2023; (15(8)):e43368 doi:10.7759/cureus.43368.

Diagnostic roles of PAX8 immunohistochemistry in ovarian tumors.

Kim J, Kim NY, Pyo JS, et al.

Pathology, research and practice 2023; (250()):154822 doi:10.1016/j.prp.2023.154822.

Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.

How JA, Legarreta AF, Handley KF, et al.

American journal of obstetrics and gynecology 2024; (230(5)):544.e1-544.e13 doi:10.1016/j.ajog.2024.01.002.

Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review.

Gao L, Huang T, Zhong L, et al.

Reproductive sciences (Thousand Oaks, Calif.) 2024; (31(6)):1626-1631 doi:10.1007/s43032-023-01443-1.

A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.

Dantkale KS, Agrawal M

Cureus 2024; (16(1)):e52650 doi:10.7759/cureus.52650.

Ovarian Yolk Sac Tumors: Is Fertility Preservation Possible?

Behnamfar F, Nazemi M, Mohamadi B

Advanced biomedical research 2024; (13()):12 doi:10.4103/abr.abr_112_21.

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.

Sama S, Rosqvist S, Savage T, et al.

Gynecologic oncology reports 2024; (53()):101412 doi:10.1016/j.gore.2024.101412.

Ovarian sclerosing stromal tumor mimicking malignancy: case series and literature review.

Skuk E, Cvjetićanin B, Pirš B, et al.

Archives of gynecology and obstetrics 2024; (310(2)):1171-1177 doi:10.1007/s00404-024-07520-3.

The unique metabolome of clear cell ovarian carcinoma.

Ji JX, Hoang LN, Cochrane DR, et al.

The Journal of pathology 2024; (264(2)):160-173 doi:10.1002/path.6329.

Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.

Au-Yeung G, MacArthur E, Chan J, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2024; (44(3)):e431818 doi:10.1200/EDBK_431818.

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

Grisham R, Monk BJ, Van Nieuwenhuysen E, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(11)):101832 doi:10.1136/ijgc-2024-005919.

Appearances Can Be Deceiving: A Case Report of Asymptomatic Appendiceal Goblet Cell Adenocarcinoma Presenting as an Ovarian Tumor.

Fukasawa H, Gou R, Tanaka K, et al.

Case reports in oncology 2024; (17(1)):1214-1221 doi:10.1159/000541626.

Clinicopathological Analysis of Ovarian Neoplasms at a Tertiary Care Teaching Institute of North Malabar: A Four-Year Retrospective Study.

Ramakrishnan J, Singh MN, Paul B, Puthen Parambath S

Cureus 2025; (17(1)):e77574 doi:10.7759/cureus.77574.

Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.

Phuong DJ, Pirtz MG, Ralston CQ, et al.

Cancers 2025; (17(4)) doi:10.3390/cancers17040604.

Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer.

Fumagalli D, Jayraj A, Olearo E, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(3)):101664 doi:10.1016/j.ijgc.2025.101664.

Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

Blanc-Durand F, Ngoi N, Lim D, et al.

Cancer treatment reviews 2025; (138()):102977 doi:10.1016/j.ctrv.2025.102977.

Serous borderline ovarian tumor and low-grade serous ovarian cancer.

Sandrasegaran K, Das A, Shah A, et al.

Abdominal radiology (New York) 2026; (51(3)):1541-1553 doi:10.1007/s00261-025-05143-z.

Late retroperitoneal recurrence of adult-type ovarian granulosa cell tumors: Two case reports and literature review.

Wang Y, Liu T, Deng X, Sun S

Science progress 2025; (108(3)):368504251376404 doi:10.1177/00368504251376404.

HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.

Shen HP, Lee MY, Chao WR, et al.

Taiwanese journal of obstetrics & gynecology 2025; (64(5)):802-808 doi:10.1016/j.tjog.2025.04.013.

Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.

Tarney CM, Mhawech-Fauceglia P, Ogata JD, et al.

Clinical proteomics 2025; (22(1)):33 doi:10.1186/s12014-025-09557-1.

A endometrial malignant tumor with yolk sac tumor component: a case report and literature review.

Cui Z, Shan Y, Chu H, Chen A

Frontiers in oncology 2025; (15()):1551266 doi:10.3389/fonc.2025.1551266.

THBS1 Contributes to Chemoresistance in Ovarian Clear Cell Carcinoma via Promoting Epithelial-Mesenchymal Transition.

Ye D, Liu Y, Cheng A, et al.

The journal of gene medicine 2025; (27(12)):e70058 doi:10.1002/jgm.70058.

Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.

Kabirian R, Gaillard T, Bello-Roufai D, et al.

Bulletin du cancer 2026; (113(4)):533-540 doi:10.1016/j.bulcan.2025.11.005.

Immunohistochemical Expression of p53 in Epithelial Ovarian Carcinoma and Its Correlation with Clinicopathological Parameters.

Sharmin F, Noor-E-Ferdous NE, Akhter L, et al.

South Asian journal of cancer 2025; (14(3)):480-484 doi:10.1055/s-0045-1809307.

Targeting RAS-RAF-MEK-ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework.

Bartl T, Cacsire Castillo-Tong D

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(4)):104485 doi:10.1016/j.ijgc.2026.104485.